NCT06476093

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer: a Single-arm, Prospective, Exploratory Clinical Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: The First People's Hospital of Lianyungang · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Detailed description

Anlotinib indication: Anlotinib is a novel oral multi-target receptor tyrosine kinase inhibitor, which has been shown to inhibit tumor growth by suppressing signaling pathways involving angiogenesis and cell proliferation. It has been approved by the Chinese National Medical Products Administration as a third-line therapy for NSCLC. SRT indication: SRT（Stereotactic Radiation Therapy） is a form of local radiation therapy that delivers high doses of radiation in a limited number of treatments. Within Chinese guidelines and consensus, it is clearly defined that limited intracranial metastases can be treated with SRT instead of WBRT (Whole Brain Radiotherapy), achieving comparable or even superior efficacy while better preserving neurocognitive function.

Conditions

• Non-Small-Cell Lung Cancer
• Brain Metastases

Interventions

Type	Name	Description
DRUG	Anlotinib hydrochloride	Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends

Timeline

• Start date: 2024-07-01
• Primary completion: 2026-12-31
• Completion: 2027-02-28
• First posted: 2024-06-26
• Last updated: 2024-06-26

Locations

1 site across 1 country: China